In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation

Why bone drug rebounds matter

Many older adults take medicines to strengthen fragile bones and prevent fractures. One powerful drug, denosumab, can build bone impressively—but when it is stopped, patients can suddenly lose bone and suffer spine fractures. This study asks whether a new kind of medicine, aimed at the cells that become bone-eating cells, could prevent that dangerous “rebound” without canceling out the gains from denosumab. The researchers explore this idea using advanced computer simulations instead of testing a real drug in people.

How bones constantly renew themselves

Our bones are not rigid statues; they are living tissues renewed by two main cell types. Osteoclasts dig away old or damaged bone, while osteoblasts fill in the gaps with new bone. Together they keep the skeleton strong. In osteoporosis, this balance tips so that removal outpaces rebuilding, leading to thinner, weaker bone and a higher risk of fractures from minor falls. Treatments try to slow the bone eaters, boost the bone builders, or both. Denosumab works by blocking a signal that normally tells immature cells to mature into active osteoclasts, sharply reducing bone breakdown.

Why stopping denosumab can be risky

Denosumab is usually given every six months and is very effective while treatment continues. But when it is stopped—because of side effects, other illnesses, or a planned “drug holiday”—many patients lose bone quickly and some suffer multiple spine fractures. Clinical and laboratory studies suggest that during denosumab treatment, a reservoir of osteoclast precursors accumulates. These cells are primed but held back from becoming full bone-eating cells. Once denosumab is withdrawn, the brake is released. The precursors rush to become active osteoclasts, triggering a burst of bone removal that outpaces new bone formation, even though some modeling-type bone building stimulated by denosumab had been beneficial.

A computer test bed for a new drug idea

The authors used a detailed in silico (computer-based) model called V-Bone, which represents bone structure, mechanical loading, signaling molecules, and the life cycles of bone cells in three dimensions over time. They extended this platform to include how bone mineral hardens and how certain growth factors couple bone removal to bone formation. First, they checked that the model could reproduce known patterns: the rebound in bone loss after stopping denosumab, the way denosumab shifts bone formation toward modeling on previously untouched surfaces, and the effects of switching from denosumab to the common pill bisphosphonate alendronate. The simulations matched clinical trends, building confidence that the virtual experiments were biologically realistic.

Targeting the troublemaking precursor cells

With the model validated, the team tested a hypothetical “osteoclast precursor inhibitor” (OCPI), a drug that would selectively push osteoclast precursors into controlled cell death, without directly touching bone-forming osteoblasts. When denosumab was stopped and treatment switched to alendronate, both bone-removing and bone-forming cells were dampened, and bone volume tended to drift downward over time—mirroring clinic results. In contrast, when the switch was to OCPI, the simulations showed that precursor numbers fell, active osteoclasts declined without a pronounced rebound, and osteoblast activity remained relatively favored. Bone volume stabilized and then increased, especially when OCPI was used at higher intensity. Combining denosumab with high-intensity OCPI during treatment, then continuing OCPI alone, nearly abolished the rebound in bone loss, while preserving the beneficial modeling-based bone building that denosumab induces.

What this could mean for future patients

The study does not test a real drug in animals or humans; instead, it provides a proof of concept that a future medicine aimed at osteoclast precursors could solve a stubborn clinical problem: rapid bone loss and fractures after stopping denosumab. By acting “upstream” on the cells that give rise to bone eaters, OCPI-like drugs might maintain bone gains and reduce fracture risk, without the unwanted dampening of bone formation seen with current follow-on therapies. The work also highlights how sophisticated computer models can be used early in the drug-development pipeline to explore ideas, refine strategies, and focus laboratory and clinical research on the most promising options.

Citation: Kim, Y.K., Kameo, Y., Tanaka, S. et al. In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation. npj Syst Biol Appl 12, 40 (2026). https://doi.org/10.1038/s41540-026-00668-5

Keywords: osteoporosis treatment, denosumab rebound, osteoclast precursors, in silico modeling, bone loss prevention